Data from LithiX HC-IVL systems from Elixir Medical matured during the night of safety and security after monaten

Data from LithiX HC-IVL-Systems from Elixir Medical Belgiumn nachhaltige Sicherheit und Wirksamkeit nachs Monaten

— Data from the PINNACLE I-Studie von Elixir zur Kalziumfragmentierung in calzifizierten Koronararterienläsionen were on the TCT vorgestellt —

— OCT-Ergebnisse considers a working attitude of a knitting Spektrums complexer Kalzifizierter Läsionen, more smoothly balanced and eccentric Kalziumablagerungen and Läsionen with Kalziumknötchen —

WASHINGTON, DC – 30. October 2024 – Elixir Medical, an Entwickler bahnbrechender technology for the treatment of Herz-Kreislauf-Erkrankungen, gab heute positive Sechs-Monats-Daten from the PINNACLE I-Studie bekannt, in the Sicherheit and Wirksamkeit des LithiX™ Hertz Contact (HC) Intravaskulären Lithotripsy Systems (IVL) for the treatment of mild swelling and calcification of the kidneys. The data on the Konferenz Transcatheter Cardiovascular Therapeutics^® (TCT) in Washington, DC, last year.

“In cardiology, it takes a long time for patients with calzifizierten treatments to treat their treatment and optimal PCI ergebnisse zu-erzielen,” so Dr. Johan Bennett, head of study and director of the CTO/CHIP programs at the Universitätsklinikum Leuven in Leuven, Belgium. “The Sechs-Monats PINNACLE-I-Daten are an extremely valid validation of the Wirkmechanismus of LithiX IVL, the Kalzium is an extremely complex morphological fragmentation that can lead to traumatic experiences. The process is not as simple as the standard PCI version is integrated, but there is an energetic inheritance.”

See the Ergebnisse der LithiX-Daten:

98.3% clinical follow-up (primary health and physical health) with 100% angiographic follow-up with a normal flow of skin with calcium morphologies
- For 100% of the welding work, there is a residual time of 50% and 30%.
- There are no procedural angiographic constructions, simple constructions, dissections, perforations or complex changes after the Eingriff
Hervorragende Sicherheit en Wirksamkeit with now a perioperative niece-Q-Wellen-Myokardinfarkt, was a TLF-Ereignisrate of 1.7% after 6 months ergibt

Part of the research works with optical optical tomography (OCT) during the process, a complex of the weld and the Wirksamkeit of the Kalzium fragmentation of LithiX IVL with a complex Kalzium morphology that is converted into a turn eilen.

The Ergebnisse der OCT-Teilstudie sees the Wirkung der LithiX-IVL-Behandling bij een Vielzahl von Läsionen:

In eccentric welds with 184.38 degrees maximum continuous body lime arcs with lime nuts in 33.3% of the welds:
- found 84.6% of eccentric weld documentation fractures and 30.8% of welds with two, three or more fractures showing a penetrating fracture of 0.76 mm (±0.28 mm) and a penetrating fracture of 0.51 mm (±0.23 mm) on
- 97.86% Stent expansion at the maximum Kalziums (MCS) and 101.38% Stent expansion at the minimum stent fläche (MSA)
In conzentric weldment with 317.47 degrees maximum continuous Kalzium arcs with Kalzium knitting in 29.4% of the weld:
- 94.7% of the weld documentation fractures and 42.1% of the welds with two or more fragments had a penetrating fragment of 0.85 mm (±0.36 mm) and a penetrating fragment of 0.75 mm ( ±0.29 mm) on
- 106.58% Stent Expansion in MCS and 93.95% Stent Expansion in MSA

“We have discovered LithiX, an IVL treatment of calf-resistant lesions during the course of the treatment and a better treatment for the treatment of calf-calf-lasions during recovery. We have invested the entire experience of PINNACLE-I-Studie, de nachhaltige Sicherheit und Wirksamkeit des Produkts“, says Motasim Sirhan, CEO of Elixir Medical. “Our team has developed the transformative cardiovascular technology of the Entwicklung, which is an easy and certainly a concern for the patient and can alleviate all clinical complaints for patients.”

The new LithiX Hertz Contact IVL system is the first non-energy-based IVL technology with fragmentation of the calzifizierter laser ions, which enables optimal stent expansion.¹ The Wirkungsmechanism of LithiX IVL is based on the physical principle of the Hertzian contact mechanism, while the inheritance orderlichen discretes of fragments of Kalzium übertragen is carried out, whether this is done by means of verletzungen. For this eingriff it is again an energy challenge, nor a sister investment since. The analysis of the PCI labor label is with a positive assessment and a positive learning curve.

Over the PINNACLE I Study
PINNACLE is an advanced, multi-center, single-arm clinical study into the Safety, Wirkiness and Leistungsfähigkeit of LithiX Hertz Contact Intravascular Lithotripsy (IVL) Systems for the treatment of calcified lesions. An der Studie nehmen 60 Patients und fünf Standorten in Belgium en de Niederlanden teil. A group of 30 patients has an intravascular image from OCT. About the most important Sicherheit and Wirksamkeit, a message from this month is shown with a different message.

About the LithiX-Hertz contact system for intravascular lithotripsy
The LithiX Hertz Contact IVL System is a transcatheter device mounted on a semi-conformal balloon. The system is designed in such a way that it is a fragmentation of the Kalziums into a broad spectrum from the medium to the extreme Kalzium morphologies, in which case there is more discrete focal tension over the contact points of the metallurgy. This unique mechanism of the LithiX Hertz Contact IVL System makes it possible to proceed with the treatment with peace of mind. Because these external sources have no external influence, they are positive about the certainty, effect and arguments of the PCI.

The LithiX IVL system is no longer suitable for packaging in the US.

Uber Elixir Medical
Elixir Medical Corporation, a private company with Sitz in Milpitas, California, operates railroad-wide platforms for performing corn and peripheral artery disease. These transformative technologies have opened up a wide variety of cardiovascular diseases, leaving millions of patients with clinical discomfort. Go to www.elixirmedical.com and to LinkedIn and X.

# # #

Resources contact:
Emma Yang
Emma Yang, healthcare trading
908-391-7197
(email protected)

References:
1.Cialdella P, Sergi SC, Zimbardo G, Donahue M, Talarico GP, Lombardi d’Aquino UM, Di Fusco P, Calò L. Calcified coronary lesions. Eur Hart J Suppl. April 26, 2023; 25 (Supplement C): C68-C73. doi: 10.1093/eurheartjsupp/suad009. PMID: 37125323; PMCID: PMC10132609.